Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Bearish
2
Neutral
7
Bullish
5
Bearish
11
Neutral
7
Bullish
28
Bearish
9
Neutral
0
Bullish
23
Discovery themes featuring this stock
Hester Biosciences Limited is a leading animal healthcare company in India, specializing in poultry and large animal vaccines. Its strategic focus on biotechnology is highlighted by the recent approval of the H9N2 Avian Influenza vaccine, expanding its poultry vaccine portfolio. The company has successfully doubled its drug product capacity with the new fill/finish facility, supporting increased manufacturing capabilities. Hester's strategic shift aims to reduce dependence on tender-driven revenues, focusing on direct engagement with commercial markets. The company continues to invest in operational discipline, resulting in substantial improvements in profitability.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,011 Cr
Low Risk
37.6
36.7
0.4
5.6
2,661.65
1,250.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
243.00 | 2,234 Cr | — | 2.38 | 0.08 | -10.13 | 0.77 | -3.81 | ||
1642.00 | 2,206 Cr | 18.99 | 3.32 | 0.61 | 15.49 | 19.85 | 13.61 | ||
2366.60 | 2,011 Cr | 37.55 | 5.58 | 0.47 | 15.45 | 14.34 | 8.48 | ||
3190.90 | 1,974 Cr | 41.03 | 6.00 | 0.05 | 14.62 | 15.37 | 8.81 | ||
228.50 | 1,974 Cr | 39.89 | 1.43 | 0.00 | 3.57 | 4.36 | 2.47 | ||
802.20 | 1,785 Cr | 49.46 | 5.50 | 0.00 | 9.40 | 12.54 | 7.50 | ||
857.35 | 1,774 Cr | 26.69 | 3.05 | 0.73 | 11.44 | 14.90 | 7.32 | ||
| Median: 7 Co. | — | 857.35 | 1,974 Cr | 38.72 | 3.32 | 0.08 | 11.44 | 14.34 | 7.50 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Hester Biosciences Ltd (HESTERBIO) is currently trading at 2,366.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Hester Biosciences Limited is a leading animal healthcare company in India, specializing in poultry and large animal vaccines. Its strategic focus on biotechnology is highlighted by the recent approval of the H9N2 Avian Influenza vaccine, expanding its poultry vaccine portfolio. The company has successfully doubled its drug product capacity with the new fill/finish facility, supporting increased manufacturing capabilities. Hester's strategic shift aims to reduce dependence on tender-driven revenues, focusing on direct engagement with commercial markets. The company continues to invest in operational discipline, resulting in substantial improvements in profitability.
Over the past 52 weeks, Hester Biosciences Ltd has traded between a low of ₹1,250.95 and a high of ₹2,661.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Hester Biosciences Ltd has a market capitalization of approximately 2,011.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Hester Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,011.45 Cr, Hester Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Hester Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Hester Biosciences Ltd is 37.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Earnings Call/Transcript
Hester Biosciences has scheduled its Q1FY27 earnings conference call on 30 July 2026 at 14:00 IST, to be held after the announcement of quarter ended 30 June 2026 results; registration details provided.
Earnings Call/Transcript
Hester Biosciences scheduled an investor earnings conference call on 2026-07-30 at 14:00 (IST) to discuss Q1 FY27 results (post results announcement). Dial-in/registration details provided.
Regulatory/Compliance Filing
Hester Biosciences Ltd informed that NSE and BSE on 24 July 2026 granted no-objection letters approving reclassification of Ravin Gandhi and Bela Gandhi from Promoter group to Public category.
Regulatory/Compliance Filing
Hester Biosciences: NSE and BSE granted no-objection letters (24-Jul-2026) approving re-classification of Ravin Gandhi and Bela Gandhi from Promoter Group to Public category; NOCs enclosed.
Board Meeting
Hester Biosciences Ltd informed exchanges that its Board will meet on 2026-07-30 to consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.
Board Meeting
Hester Biosciences Ltd informed exchanges that its Board will meet on 2026-07-30 to consider and approve unaudited standalone and consolidated financial results for Q1 (quarter ended 30 June 2026).
